EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Residual Inflammatory Risk of Heart Failure and Atherosclerotic CVD in Diabetes

Kershaw V Patel, Leonard Chiu, Katelyn R Garcia, L Maria Belalcazar, Matthew W Segar, Javed Butler, Mark Espeland, Christie M Ballantyne, Ambarish Pandey

JACC: Heart Failure · 2026-11 · 14 (11) · 103296

DOI: 10.1016/j.jchf.2026.103296 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Heart Failure, 2026-11. Verfasst von Kershaw V Patel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Heart Failure, Interleukin-6, C-Reactive Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: High-sensitivity C-reactive protein (hs-CRP) and interleukin (IL)-6 are inflammatory biomarkers associated with cardiovascular disease (CVD) risk. OBJECTIVES: This study aims to examine the associations of hs-CRP and IL-6 with risk of atherosclerotic cardiovascular disease (ASCVD) and incident heart failure (HF) and to evaluate the effect of an intensive lifestyle intervention (ILI) targeting weight loss on IL-6 in type 2 diabetes (T2D). METHODS: Look AHEAD trial participants with T2D and overweight/obesity underwent measurement of hs-CRP (n = 1,902) and IL-6 (n = 1,507) at baseline. Associations of inflammatory biomarkers with risk of ASCVD and incident HF were evaluated using adjusted Cox models. Associations were evaluated among participants with and without CVD history. A generalized linear model compared 1-year change in IL-6 across the ILI and diabetes support and education treatment groups. RESULTS: Median baseline hs-CRP and IL-6 were 4.04 mg/L and 2.07 pg/mL, respectively. After adjusting for demographics, CVD risk factors, and statin use, hs-CRP was not significantly associated with the risk of ASCVD or incident HF. Higher IL-6 was significantly associated with higher risk of incident HF in the overall cohort (HR: 1.43; 95% CI: 1.16-1.75 per 1-SD higher log[IL-6]) with a stronger association among those with no history of CVD (HR: 1.92; 95% CI: 1.38-2.66 per 1-SD higher log[IL-6]; IL-6 × CVD history P interaction < 0.05). The reduction in IL-6 at 1-year was greater with the ILI than with the diabetes support and education (-28.7% vs -11.8%; P = 0.01). CONCLUSIONS: Among adults with T2D and overweight/obesity, IL-6 identified residual inflammatory risk of incident HF, particularly among adults with no CVD history. An ILI targeting weight loss reduced IL-6 over 1-year of follow-up. (Look AHEAD: Action for Health in Diabetes [Look AHEAD]; NCT00017953).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Heart FailureInterleukin-6C-Reactive ProteinAtherosclerosisInflammationHumansFemaleMaleMiddle AgedBiomarkersAgedObesityRisk FactorsIncidenceWeight Loss

Stichwörter der Autor:innen

atherosclerotic cardiovascular diseaseheart failureinflammationintensive lifestyle interventionobesitytype 2 diabetes

Substanzen

Interleukin-6C-Reactive ProteinBiomarkers

Autor:innen und Institutionen

  • Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA.
  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Biostatistical Sciences, Wake Forest School of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA.
  • Division of Endocrinology and Metabolism, University of Texas Medical Branch, Galveston, Texas, USA.
  • Department of Cardiology, Texas Heart Institute, Houston, Texas, USA.
  • Baylor Scott and White Research Institute, Dallas, Texas, USA; Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.

Zitieren

APA

Patel, K. V., Chiu, L., Garcia, K. R., Belalcazar, L. M., Segar, M. W., Butler, J., Espeland, M., Ballantyne, C. M., & Pandey, A. (2026). Residual Inflammatory Risk of Heart Failure and Atherosclerotic CVD in Diabetes. JACC: Heart Failure, 14(11), 103296. https://doi.org/10.1016/j.jchf.2026.103296

Vancouver

Patel KV, Chiu L, Garcia KR, Belalcazar LM, Segar MW, Butler J, et al. Residual Inflammatory Risk of Heart Failure and Atherosclerotic CVD in Diabetes. JACC: Heart Failure. 2026;14(11):103296. doi:10.1016/j.jchf.2026.103296

BibTeX
@article{Patel2026,
  author = {Patel, Kershaw V and Chiu, Leonard and Garcia, Katelyn R and Belalcazar, L Maria and Segar, Matthew W and Butler, Javed and Espeland, Mark and Ballantyne, Christie M and Pandey, Ambarish},
  title = {Residual Inflammatory Risk of Heart Failure and Atherosclerotic CVD in Diabetes},
  journal = {JACC: Heart Failure},
  year = {2026},
  volume = {14},
  number = {11},
  pages = {103296},
  doi = {10.1016/j.jchf.2026.103296}
}
Kostenlos starten →